Based on initial clinical trials, the most commonly reported side effects, listed from most to least common, were: Nausea: 44% of people on a weekly Wegovy maintenance dose (2.4 mg injection), and 39% of people receiving the highest dose (7.2 mg injection) experienced nausea
The same active ingredient, tirzepatide, is available under the brand name Zepbound for chronic weight management
These were 0.12 for MI, 0.21 for stroke, and 0.11 for HF [24]
Asthma : People with asthma should avoid inhaled glutathione (like nebulizer treatments) because it can trigger breathing problems
Thus, understanding how pharmacy and medical benefit design affects GLP-1 coverage is critical
The Danish pharma giant added that there are key measurement limitations in the study, which need to be considered while interpreting the findings